Reviva Pharmaceuticals Holdings, Inc. (RVPH) News
Filter RVPH News Items
RVPH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RVPH News Highlights
- For RVPH, its 30 day story count is now at 4.
- Over the past 15 days, the trend for RVPH's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC, ADV and ARM are the most mentioned tickers in articles about RVPH.
Latest RVPH News From Around the Web
Below are the latest news stories about REVIVA PHARMACEUTICALS HOLDINGS INC that investors may wish to consider to help them evaluate RVPH as an investment opportunity.
Karuna downgraded, Arm target raised: Wall Street's top analyst callsKaruna downgraded, Arm target raised: Wall Street's top analyst calls |
Life Science Investor Forum: Presentations Now Available for Online ViewingCompany Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Investor Forum sponsored by Zacks Small-Cap Research. held December 14th are now available for online viewing. REGISTER NOW AT: https://bit.ly/41oBqxg The company presentations will be available 24/7 for 90 days. Investors, adv |
Life Science Investor Forum Agenda Announced for December 14th, 2023NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum to be held December 14th. This event is sponsored by Zacks Small-Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/3tcvQkSIt is recommended that investors pre-register and run the online system check to expedite participat |
Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor ForumCUPERTINO, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will participate live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferen |
Reviva Pharmaceuticals to Participate in The Benchmark Company’s Upcoming Discovery One-on-One Investor ConferenceCUPERTINO, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO, and Narayan Prabhu, CFO of Reviva, will participate in The Benchmark Company’s Discovery One-on-One In |
Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesCUPERTINO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it has closed its previously announced registered direct offering with several healthcare-focused institutional investors, and an investment vehicle managed |
RVPH: Raise & RECOVER Results ReviewBy John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT 3Q:23 Financial and Operational Results On November 14, 2023, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported 3Q:23 financial and operational results and filed its Form 10-Q with the SEC. The most important news since the previous quarterly update was the topline data for the Phase III RECOVER trial evaluating |
Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesCUPERTINO, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors, and an investment vehicle managed by a firm affiliated wit |
Reviva Pharmaceuticals Holdings Inc Reports Q3 2023 Financial ResultsBrilaroxazine's Positive Trial Outcomes Amidst Increased Net Loss |
Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights- RECOVER global Phase 3 trial successfully met all primary and secondary endpoints with statistically significant and clinically meaningful reductions across all major symptom domains at week 4 with 50 mg of brilaroxazine vs. placebo in schizophrenia – - Consistent Phase 3 RECOVER and Phase 2 REFRESH findings reinforce meaningful improvements across domains, well-tolerated safety, and low discontinuation rates for brilaroxazine vs. placebo – - Topline data from 1-year open-label extension (OLE) |